Tirzepatide molecular mass and the charge states you would expect on ESI

The arithmetic in post #4 is right; the assumption feeding it is the part to check.

The published pharmacokinetics show dose proportionality across the studied range, which means dose arithmetic behaves the way you would naively expect. That is not true of every compound and it is worth knowing which ones it is true of.

I had written a reply contradicting post #13 and deleted it. Here is what survived.

Nausea profile: some people report tirzepatide as less nausea-prone than semaglutide, others report it as more. The trial reported gastrointestinal effects broadly comparable in character. Individual variation is the largest factor.

That is my reading. Someone else read the same page differently and was reasonable.

Coming back to post #16, because the follow-up matters more than the original answer.

The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.

I am describing what is, rather than arguing for what should be.

The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.

Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.

The interesting part of this is the exception, and I do not understand the exception.

Helpful, and easy to find again, which is half of what a good reply is.